ePrints

Novel aspects of accumulation dynamics and AP composition in transgenic models of AD

Lookup NU author(s): Professor Raj KalariaORCiD

Downloads

Full text for this publication is not currently held within this repository. Alternative links are provided below where available.

Abstract

A homogeneous time-resolved fluorescence immunoassay for detection of beta-amyloid (Abeta) peptides has been adapted for quantification of Abeta(40) and Abeta(42) accumulation in brains of APP695SWE transgenic mice. These over-express human betaAPP(swe), beta-amyloid precursor protein (beta-APP) containing the K670N/M671L 'Swedish' familial Alzheimer's disease (FAD) mutation. Both peptides start to accumulate in this line from about 260 to 280 days of age. Co-expression of a human presenilin-1 (PS1) transgene containing the A246E FAD mutation accelerates deposition and also favors-at least initially-accumulation of Abeta(42) so that the Abeta(2):Abeta(40) ratio of peptides from 7- to 12-month-old APP695SWE x PS1A246E animals is significantly elevated above that observed throughout the lifetime of APP695SWE mice. These findings, supported by parallel immunohistochemical staining and surface-enhanced laser desorption/ionization time-of-flight (SELDI-TOF) mass spectrometry data, offer important longitudinal characterization of two mouse models of cerebral amyloidosis. Application of the same extraction and quantitation procedures to samples of temporal cortex from AD sufferers indicates however that Abeta(40) is only a minor component of beta-amyloid in humans. (C) 2004 Elsevier Inc. All rights reserved.

Publication metadata

Author(s): Lewis HD, Beher D, Smith D, Hewson L, Cookson N, Reynolds DS, Dawson GR, Jiang M, Van der Ploeg JHX, Qian S, Rosahl TW, Kalaria RN, Shearman MS

Publication type: Article

Publication status: Published

Journal: Neurobiology of Aging

Year: 2004

Volume: 25

Issue: 9

Pages: 1175-1185

ISSN (print): 0197-4580

ISSN (electronic): 1558-1497

Publisher: Elsevier

URL: http://dx.doi.org/10.1016/j.neurobiolaging.2003.12.009

DOI: 10.1016/j.neurobiolaging.2003.12.009

Altmetrics

Share